Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival

Table 1 Evaluated parameters in formalin-fixed paraffin-embedded tissue

No.	Case/groups	HMGA1 (%)	hTERT (%)	Ki-67 (%)
1	Case	2.6	11.5	45
2	controls (n = 15, median with range)	0.0 (0-0)	0.0 (0.0-0.05)	0.0 (0-0)
3	GBM (n = 30, median with range)	14.55 (2.3-23.9)	25.76 (10.5-44.75)	28 (6.5-80)

HMGA1: High mobility group-A1; hTERT: Human telomerase reverse transcriptase; GBM: Glioblastoma-multiforme.

Table 2 Parameters evaluated in circulation (serum/plasma)

No.	Case/group	NLR	hTERT	YKL-40	TIMP-1	1IL-6	2HMGA1
1	Case	3.9	6.125	71.47	80	645.207	16.8
2	Control (n = 15)	1.6 (0.87-28)	1.14 (0.22-1.585)	18.3 (1.12-66.7)	23.7 (10.3-88.4)	48.9 (6.71-72.8)	-
3	GBM (n = 30)	5.58 (3.1-18)	2.18 (0.565-8.84)	101.2 (21.2-198.8)	93.8 (37.2-185.1)	197.6 (59.2-803.7)	30.613

¹n = 15; hTERT, TIMP-1 and YKL-40, IL-6 quantified in ng/L, ng/mL and pg/mL respectively;

²HMGA1 quantified in terms of protein band density. NLR: Neutrophil lymphocyte ratio; HMGA1: High mobility group-A1; hTERT: Human telomerase reverse transcriptase; IL-6: Interleukin-6; TIMP-1: Tissue inhibitor of metalloproteinases-1; YKL-40: Human chitinase-3-like-protein-1.